News

A partnership between IRICoR and Ovarian Cancer Canada
 
For the past 10 years, IRICoR has targeted the best academia-based projects in order to translate them into innovative therapies that will benefit patients. So far, IRICoR has made close to 80 financings in high-quality projects, established more than 20 strategic partnerships with key players, both locally and internationally, towards initiation of 7 […]

Montréal and Martinsried/Munich, 30 January 2020 – IRICoR, a pan-Canadian drug discovery research commercialization centre and the Université de Montréal (UdeM) announce today that they have entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with Medigene, a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies.
UdeM’s research team, led by […]

Photo credit : @mirrorimagemedia, NFB project #MySTEMjob
IRICoR is pleased to announce the appointment of its Chief Executive Officer, Dr. Nadine Beauger, to Immune Biosolutions Board of Directors.
Immune Biosolutions is an early-stage biopharmaceutical company focused on the discovery, engineering and development of humanized chicken antibodies that target intractable membrane proteins with a validated therapeutic potential. Immune Biosolutions’ current pipeline of therapeutic […]

Shape the future of biotech in Canada
 

 
Presented by BIOTECanada, BIONATION 2020 is the first-ever Canadian national forum on biotechnology.
During this two-day event, industry leaders, technology executives and senior government officials from across the country will come together to discuss the state of biotechnology in Canada and develop an innovation action plan for moving forward.
BIONATION will raise the profile of Canada’s […]

Mission en innovation au Royaume-Uni : A successful experience
 
Délégués de la mission au Francis Crick Institute
 
From December 9 to December 13, 2019, on the occasion of the Genesis Conference, the Ministry of Economy and Innovation, the Quebec Government Office in London and the High Commission of Canada in the United Kingdom organized an economic mission in research and innovation in […]

Montreal, November 18, 2019 —IRICoR held the first of its brand new series of Lunch & Learn conferences on November 11. Organized in collaboration with the Lavery law firm and intended for research and life sciences professionals, its theme was “Patents and rights of inventors in academia”. The event was a resounding success.
The conference brought together close to 60 participants, including […]

 
IRICoR is very excited to launch its new series of Lunch and Learn conferences, aimed at research and life sciences professionals. Over the coming months, these workshops will address topics as varied as business, innovation, drug discovery, and more.
Please join us on November 11, from 12:00 pm to 1:30 pm, to take part in the first conference on intellectual property, […]

IRICoR is proud to welcome Ms. Elizabeth Wong and Ms. Ferima Sanogo to its team, as Business Development Analyst and Project Manager, respectively.

 
Reporting to the VP, Business Development, Ms. Wong’s responsibilities will include evaluating projects selected for their commercial and scientific potential for the purpose of positioning them for company start-up opportunities, while also preparing market and competition assessments for […]

IRICoR is proud to announce, as part of his joint project with the Oncopole, LeadAction Onco, an investment of $2.4 million dollars over two years, to support four flagship cancer drug discovery projects in Canada. This major announcement was made today by Mr. Pierre Fitzgibbon, Minister of Economy and Innovation, on the occasion of the opening of the Quebec Pavilion […]

IRICoR is pleased to announce the appointment of three new Directors to its Board: Ms. Annie Gauthier – lawyer and partner at the law firm BCF, Bettina Hamelin – President and CEO of Ontario Genomics and Mr. Bernard Lachapelle – President of The JBL Group Inc.
Annie Gauthier
Bettina Hamelin
Bernard Lachapelle
 
 
 
 
 
 
 
 
 
 
 
 
These three new Directors bring a range of expertise complementary to that […]